Tagged with Investment

China A decade on from its launch, the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) initiative has made some significant wins but remains some way from fulfilling the vision of a fully integrated internationally competitive bay area to rival that of its US west coast namesake.   Staggering Fundamentals Home to 87…

Hong Kong 2018 marked a significant milestone in Hong Kong’s journey towards creating a vibrant biotech market for investors which allows Asian innovation to receive the funding it needs to progress. It was in that year that the Hong Kong Stock Exchange (HKEX) launched the bold and visionary move of allowing clinical-stage…

Morocco Fadela Benjelloun, executive director of LEMM, the association of multinational pharma companies in Morocco, looks back on the evolution of the Moroccan pharma market over the past three years, examines the access to innovation situation today, and the impact of the generational healthcare reform currently underway in the country.  …

USA Biotech and life sciences companies have a habit of clustering together, creating shared ecosystems to drive innovation. For going on 12 years Johnson & Johnson Innovation (JLABS), has been supporting this strength in numbers philosophy, finding, funding and incubating promising startups under a scheme of open innovation in its shared…

China Ongoing geopolitical tensions between China and the West have led the G7 group of countries to warn of the threat of “economic coercion” from China and the US to scrutinise Chinese investment in its biotech sector more closely. Against this backdrop, and despite many of the leading lights in global…

Hong Kong Albert Wong of the Hong Kong Science and Technology Parks Corporation (HKSTP) outlines how Hong Kong has developed as an innovation hub, building on its established areas of finance and trading. Wong also discusses the importance of life science companies with HKSTP’s portfolio, the challenges of talent attraction, and the…

UAE Speaking exclusively to PharmaBoardroom, H.E. Dr Noura Al Ghaithi, Undersecretary of the Department of Health Abu Dhabi outlines Abu Dhabi’s rapid progression towards becoming a global life science hub, how the DoH is drawing on international collaborations to help solve the most burning healthcare issues, as well as the transformative…

Hong Kong Since first allowing pre-revenue biotechs to list in 2018, the Hong Kong stock exchange has welcomed 59 such companies and is now a leading vehicle for allowing Chinese biopharma to access international capital. Christina Bao, HKEX’s co-head of sales and marketing, discusses listing momentum picking up again after a rocky…

Hong Kong The Hong Kong Association of the Pharmaceutical Industry (HKAPI) represents the interests of the global R&D-based biopharmaceutical industry in Hong Kong and Macau. Senior Executive Director Sabrina Chan outlines the access to innovation scenario in the territory today, the niches in which Hong Kong stands out from the crowd as…

China First set up in 2014, the Guangdong Medical Valley is an investment incubation platform in southern China focusing on the biomedical and medical device industries. CEO Xia Jiasheng explains how the decision to set up the cluster came about, how it differs from the wealth of other science parks in…

Europe Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, critiques the draft EU Pharma Regulation from a VC perspective, arguing that the continent’s status as a medical innovation hub is at risk if the EU…

Belgium Germany and Belgium have long held an important trading relationship, says Margit Kunz of AHK Debelux, the German chamber of commerce in Belgium and Luxembourg. She outlines some of the key industrial investments and trends for German companies within Belux and why Belgium should be better known as an investment…